Drug Trial Radar · NCT05581199
To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP
Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
94
Actual
Start
Dec 15, 2022
Primary completion
Jul 20, 2026
Study completion Jul 20, 2026
Sponsor
- Lead sponsor
- Immunovant Sciences GmbHIndustry
- Sponsor type
- Industry
- First posted
- Oct 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, randomized, quadruple-blind, placebo-controlled study to evaluate the efficacy and safety of batoclimab in adult participants with active CIDP. The study includes an up to 4-week Screening Period, an up to 12-week Washout Period, a 12-week Randomized Treatment Period (Period 1), an up to 24-week Randomized Withdrawal Period (Period 2), an up to 52-week Long-term Extension (LTE) Period (optional), and Safety Follow-up 4 weeks after the last dose of study treatment. The total study duration will be up to approximately 109 weeks. Eligible participants will be assigned to one of four cohorts based upon their baseline CIDP treatment (Cohorts A and D - immunoglobulin \[Ig\] or plasma exchange \[PLEX\]; Cohort B - corticosteroids; Cohort C - naive or untreated in previous 3-24 months) and whether they meet diagnosis according to the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) criteria (Cohorts A, B, and C) or clinical criteria only (Cohort D) at the time of screening.
Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
Batoclimab 680 milligrams (mg) subcutaneous (SC) weeklyDrug
Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
Batoclimab 340 mg SC weeklyDrug
Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
PlaceboDrug
Matching placebo SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Period 2, Cohort A: Proportion of participants who remain relapse-free at Week 36Time frame: Week 36
Locations
98 sites in 21 countries. Site status is shown where the registry gives one.
Site Number - 1603
Scottsdale, Arizona
Site Number - 1634
Los Angeles, California
Site Number - 1625
Aurora, Colorado
Site Number - 1621
New Haven, Connecticut
Site Number - 1629
Orlando, Florida
Site Number - 1617
Ormond Beach, Florida
Site Number - 1620
Port Charlotte, Florida
Site Number - 1633
Rockledge, Florida
Site Number - 1604
St. Petersburg, Florida
Site Number - 1602
Kansas City, Kansas
Site Number - 1611
Nicholasville, Kentucky
Site Number - 1605
New York, New York
Site Number - 1610
Charlotte, North Carolina
Site Number - 1614
Portland, Oregon
Site Number - 1623
Philadelphia, Pennsylvania
Site Number - 1624
Philadelphia, Pennsylvania
Site Number -1601
Austin, Texas
Site Number - 1606
Houston, Texas
Site Number - 1628
San Antonio, Texas
Site Number - 1632
Seattle, Washington
Site Number - 1613
Milwaukee, Wisconsin
Site Number - 7750
Buenos Aires, Argentina
Site Number - 7753
Rosario, Santa Fe Province, Argentina
Site Number - 7751
Rosario, Santa Fe Province, Argentina
Site Number - 7752
San Miguel de Tucumán, Tucumán Province, Argentina
Site Number - 4681
Ghent, Oost-Vlaanderen, Belgium
Site Number - 4680
Leuven, Vlaams Brabant, Belgium
Site Number - 9105
São Paulo, Brazil
Site Number - 9103
Brasília, Federal District, Brazil
Site Number - 9101
Curitiba, Paraná, Brazil
Site Number - 9100
Ribeirão Preto, São Paulo, Brazil
Site Number - 9112
Pleven, Bulgaria
Site Number - 9111
Sofia, Sofia-Grad, Bulgaria
Site Number - 9110
Sofia, Sofia-Grad, Bulgaria
Site Number - 2600
Edmonton, Alberta, Canada
Site Number - 2603
Vancouver, British Columbia, Canada
Site Number - 4740
Copenhagen, Denmark
Site Number - 3241
Turku, Southwest Finland, Finland
Site Number - 6706
Berlin, Germany
Site Number - 6705
Bochum, North Rhine-Westphalia, Germany
Showing 40 of 98 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.